Multi-Cancer Blood Tests to Be Trialed at UK GP Surgeries

The UK is set to trial multi-cancer blood tests in some general practitioner (GP) surgeries, with the aim of detecting hard-to-diagnose abdominal cancers, including liver, ovarian, and pancreatic cancer, at an earlier stage. The initiative is part of the STRIDE-RCT trial, funded by the government and led by the University of Birmingham.

This trial will evaluate whether these blood tests are accurate enough for broader use within the National Health Service (NHS). The tests analyze blood samples for specific signs of cancer and may be able to identify the tumor's location in the body. Patients participating will provide one or two tubes of blood during routine appointments.

While the concept of a multi-cancer blood test is not new, a separate NHS trial of a test called Galleri did not meet its primary goal of reducing late-stage cancer diagnoses, though its potential benefits are still under assessment.

Experts emphasize the importance of early cancer detection. Professor Peter Johnson, NHS England's national clinical director for cancer, noted that diagnosing abdominal cancers early is particularly challenging due to symptoms often being mistaken for less serious conditions. Earlier diagnosis significantly improves a patient's chances of successful treatment and survival.

In England, approximately 71,000 individuals are diagnosed annually with bowel, small bowel, stomach, esophageal, pancreatic, liver, bile duct, gallbladder, ovarian, endometrial, kidney, bladder, and prostate cancers. Tragically, nearly 35,000 people die from these diseases each year.

Health Secretary Yvette Cooper expressed hope that simple blood tests will expedite the identification of patients requiring urgent investigation. Michelle Mitchell from Cancer Research UK added that GPs require better tools to help identify patients who need further testing, and this trial represents a significant step towards addressing that need. It is important to note that a positive result does not confirm cancer, and a negative result does not guarantee an all-clear.